| Literature DB >> 25305566 |
Miey Park1, Han-Sung Kim1, Kyu Sung Shin1, Hyun Soo Kim1, Ji Young Park1, Wonkeun Song1, Hyoun Chan Cho1, Kyu Man Lee1, Jae-Seok Kim2.
Abstract
Here, we examined the distribution of pneumococcal serotypes and the antibiotic susceptibility of Streptococcus pneumoniae in clinical blood isolates. The serotypes of 91 S. pneumoniae blood isolates, collected from January 2003 to March 2014, were identified by multiplex PCR and sequencing. The most common serotypes were 19F, 19A, 3, 4, and 14, accounting for 53.8% of the total. The serotype coverage rates of pneumococcal conjugated vaccine (PCV) 7, PCV10, and PCV13 were different during three test periods: 38.7%, 70.9%, and 93.5% in period I (2003-2005), 46.8%, 50.0%, and 75.0% in period II (2006-2008), and 28.5%, 32.1%, and 64.2% in period III (2009-2014), respectively. By contrast, the number of non-PCV13 serotypes increased from 6.4% in period I to 25% and 35.7% in periods II and III, respectively. The susceptibility of non-PCV13 serotypes to antimicrobial agents (penicillin, erythromycin, cefotaxime, and meropenem) was higher than that of PCV serotypes. In particular, non-PCV13 serotypes showed 100% and 95% susceptibility to penicillin and cefotaxime, respectively. Serotypes 19A and 19F showed high prevalence (79.1%) among 24 multi-drug resistant (MDR) isolates. Notably, all serotype 19A isolates were MDR. From January 2003 to March 2014, the proportion of non-PCV13 serotype pneumococci in blood isolates increased whereas the coverage rate of PCV13 decreased. Effective pneumococcal vaccines are required to protect against MDR serotype 19A isolates and the increasing number of non-PCV13 serotypes.Entities:
Keywords: Multi-drug resistant (MDR) isolates; Non-PCV13 serotypes; Pneumococcal conjugated vaccine; Serotypes; Streptococcus pneumoniae
Mesh:
Year: 2014 PMID: 25305566 DOI: 10.1016/j.vaccine.2014.09.062
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641